Journal of Agricultural and Food Chemistry · 2024 · 10 citations · 40 references
Life SciencesMolecular BiologyToxicologyGenome EditingInnate ImmunityMechanisms Of ToxicityCrispr-cas SystemsHepatic ToxicityHepatotoxicity MechanismsMechanisms Of Toxic InjuryMolecular Mechanisms Of ToxicityToxin-mediated DiseaseCrispr-cas9 Genome EditingHepatotoxic MechanismsLiver Injury MechanismsLiver Toxicity MechanismsPyroptosis MechanismsToxin IdentificationToxin-induced Liver InjuryToxin-mediated Tissue Damage
Multiple compounds are related to the development of liver injury, such as toxins, drugs, and environmental pollutants. Although there are reports that the T-2 toxin can cause liver injury, its toxic mechanism remains unclear, which further impedes the development of effective antidotes. In this study, CRISPR-Cas9 genome-wide screening technology was used to identify transformation-related protein 53 inducible nuclear protein 1 (trp53inp1) as a toxic target of the T-2 toxin. Mechanism studies have shown that the T-2 toxin induced pyroptosis of macrophages (J774A.1 cells) by activating the trp53inp1/NF-κB/NLRP3/GSDMD-N pathway, leading to a subacute liver injury. Also, the new drug berberine (BER) identified through virtual screening significantly alleviated the subacute liver injury by competitively binding trp53inp1 via His224; the effect was better than those of the positive control drugs N -acetylcysteine (NAC) and disulfiram (DSF). In summary, the above results indicate that trp53inp1 is a key target for T-2 toxin to induce subacute liver injury and that inhibiting macrophage pyroptosis is a new method for treating liver injury. In addition, this study provides a new method and strategy for the discovery of key disease targets and the search for effective drugs.
40
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem, Neville E. Sanjana, Ella Hartenian et al. · Science · 2013 · 5.5K citations · Full text
Wei Li, Han Xu, Tengfei Xiao et al. · Genome biology · 2014 · 2.8K citations · Full text
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis et al. · Science · 2020 · 1.4K citations · Full text
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Fiona M. Behan, Francesco Iorio, Gabriele Picco et al. · Nature · 2019 · 1.4K citations · Full text
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung, Silvana Konermann, Jonathan S. Gootenberg et al. · Nature Protocols · 2017 · 1.3K citations · Full text